Haemonetics Corporation Stock News

Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.

Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.

Boston Trust Walden Corp boosted its position in shares of Haemonetics Co. (NYSE:HAE) by 71.8% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commiss

Equities analysts forecast that Haemonetics Co. (NYSE:HAE) will announce $245.33 million in sales for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Hae

It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...

New York, April 17, 2020 -- Reportlinker.com announces the release of the report "Global Blood Lancets Market By Type By End Users By Region, Industry Analysis and Forecast,.

Haemonetics (NYSE:HAE) has had a great run on the share market with its stock up by a significant 38% over the last...

Haemonetics Co. (NYSE:HAE) was the recipient of a significant growth in short interest in the month of March. As of March 31st, there was short interest totalling 2,040,000 shares, a growth of 15.8% f

The Boston Chapter of Financial Executives International (FEI) has announced the 2020 Academic Award Recipients. The program, which has awarded close to $150,000 in the past ten years, recognizes stud

Haemonetics (HAE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Haemonetics (HAE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Haemonetics Co. (NYSE:HAE) Director Mark W. Kroll sold 10,902 shares of Haemonetics stock in a transaction that occurred on Thursday, April 9th. The stock was sold at an average price of $102.00, for

Portland, OR, April 14, 2020 -- According to the report published by Allied Market Research, the global Blood Lancets Industry contributed to $901.30 million in 2018, and is.